What is Paul Buckman’s NeuroOne (NMTC) share ownership after these grants?

After the reported grants, Buckman directly owns 178,733 shares of NeuroOne common stock. This figure reflects his position following the 41,929-share restricted stock unit award and does not include the unexercised stock options granted in the same filing.

Equity awards granted to NeuroOne (NMTC) director Paul Buckman

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NeuroOne Medical Technologies director Paul Buckman received new equity awards as compensation. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.

He was also granted 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at the end of each month. Following these awards, he directly holds 178,733 shares of common stock. These are grants, not open-market purchases.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BUCKMAN PAUL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	26,036	$0.00	--
Grant/Award	Common Stock	41,929	$0.00	--

Holdings After Transaction: Option to Purchase Common Stock — 26,036 shares (Direct); Common Stock — 178,733 shares (Direct)

Footnotes (1)

Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

Key Figures

Option grant size: 26,036 shares Option exercise price: $0.795 per share Option expiration: April 2, 2036 +3 more

6 metrics

Option grant size 26,036 shares Option to Purchase Common Stock granted on April 3, 2026

Option exercise price $0.795 per share Strike price for 26,036-share option grant

Option expiration April 2, 2036 Expiration date of stock option grant

RSU grant size 41,929 shares Restricted stock units granted on April 3, 2026

Shares held after grant 178,733 shares Total common stock directly owned after RSU grant

Vesting schedule 12 equal monthly installments Applies to both RSUs and stock option grant

Key Terms

restricted stock units, Option to Purchase Common Stock, vesting, exercise price

4 terms

restricted stock units financial

"Represents a grant of restricted stock units, which vest in 12 equal monthly installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Option to Purchase Common Stock financial

"security_title: Option to Purchase Common Stock"

vesting financial

"vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 0.7950"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

04/07/2026 - 01:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUCKMAN PAUL

(Last)

(First)

(Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE

MINNESOTA

55344

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/03/2026		A		41,929⁽¹⁾	A	$0	178,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	$0.795	04/03/2026		A		26,036		⁽²⁾	04/02/2036	Common Stock	26,036	$0	26,036	D

Explanation of Responses:

1. Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

2. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

	/s/ Emily Johns, by Power of Attorney	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did NeuroOne (NMTC) director Paul Buckman report?

Paul Buckman reported receiving equity grants from NeuroOne. He was awarded 26,036 stock options and 41,929 restricted stock units as compensation, both vesting monthly over one year, rather than buying or selling shares in the open market.

How many NeuroOne (NMTC) stock options were granted to Paul Buckman?

Paul Buckman received an option grant for 26,036 shares of NeuroOne common stock. The option carries a strike price of $0.795 per share, vests in 12 equal monthly installments over one year, and expires on April 2, 2036 if not exercised.

What are the terms of Paul Buckman’s restricted stock units in NeuroOne (NMTC)?

Buckman received 41,929 restricted stock units in NeuroOne. These RSUs vest in 12 equal monthly installments over a one-year period, with each tranche vesting at the end of the month, providing a steady stream of share-based compensation during the year.

Did Paul Buckman buy or sell NeuroOne (NMTC) shares on the open market?

The filing shows no open-market buys or sells by Paul Buckman. Instead, he acquired shares through grants: stock options and restricted stock units awarded as compensation, both recorded at a transaction price of $0.00 per share in the disclosure.

How do the NeuroOne (NMTC) equity awards to Paul Buckman vest over time?

Both the stock options and restricted stock units vest in 12 equal monthly installments. Vesting occurs at the end of each month over a one-year period, gradually delivering exercisable options and settled shares rather than all at once on a single vesting date.